# Safety of Etoricoxib (MK-0663) in Patients With Spondyloarthropathy (SpA)/Ankylosing Spondylitis (AS) in Sweden (EP07013.013.11.082)

> **NCT01327638** · — · COMPLETED · sponsor: **Organon and Co** · enrollment: 21108 (actual)

## Conditions studied

- Spondylarthropathies; Spondylitis, Ankylosing

## Interventions

- **DRUG:** etoricoxib
- **DRUG:** Other COX-2 inhibitor
- **DRUG:** nsNSAIDs

## Key facts

- **NCT ID:** NCT01327638
- **Lead sponsor:** Organon and Co
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02-15
- **Primary completion:** 2018-09-24
- **Final completion:** 2018-12-06
- **Target enrollment:** 21108 (ACTUAL)
- **Last updated:** 2024-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01327638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01327638, "Safety of Etoricoxib (MK-0663) in Patients With Spondyloarthropathy (SpA)/Ankylosing Spondylitis (AS) in Sweden (EP07013.013.11.082)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01327638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*